NSE filing, NSE: RAYMOND. Summary written from the filing by ALFA Finder's alert engine.
Raymond Ltd: key numbers
- Share price
- ₹1,060.10
- Market cap
- ₹7,057 Cr
- Revenue (annual)
- ₹2,212 Cr
- Net profit (annual)
- ₹5,341 Cr
- P/E (TTM)
- 146.9×Sector 52.2×
- Promoter holding
- 48.87%+0.00% QoQ
- FII holding
- 7.19%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Raymond Ltd
All →Raymond Earnings Call Transcript: Key Takeaways
Raymond delivers 21% revenue growth driven by a massive 72% jump in Aerospace, though engineering margins remain under pressure from high R&D expensing.
- Call
- Guides 25% growth
Raymond Investor Presentation: Key Takeaways
Q2 FY27 consolidated total income ₹683 Cr (+21%), EBITDA ₹103 Cr (15.1% margin), PAT ₹32 Cr; Aerospace outpaces Precision Tech; net cash surplus ₹77 Cr.
Raymond Results Update
Raymond's Q2 FY27 total income rose 21% to Rs 683 crore, with EBITDA up 30%. The company remains net debt free.
Raymond Q2 FY27 Results: Net Profit ₹32.1 Cr, Up 130.9% YoY
Raymond Ltd reported revenue from operations of ₹655.2 Cr (+24.2% YoY) and net profit of ₹32.1 Cr (+130.9% YoY) for Q2 FY27.
- Key figure
- Net profit ₹32.1 Cr · +130.9% YoY
Raymond Other Announcement
Raymond Limited's board approved changing its name to Raymond Aerospace, Defence & Engineering Limited. Shareholder approval, regulatory consents and consequential MOA/AOA amendments are still pending.
Raymond Convertible Warrants
Raymond corrected the EOGM notice details regarding the preferential issue of 33,28,686 warrants to Minerva Ventures Fund, clarifying post-issue shareholding percentages.
Other employee stock options announcements
All →RateGain Travel Technologies Employee Stock Options
RateGain granted 53,021 Stock Appreciation Rights under its SAR Scheme 2022 at ₹800 and ₹862.25 per unit. The grants vest over four years and are exercisable within three years of vesting.
- Execution
- Vesting over 4 years (10% Y1, 20% Y2, 30% Y3, 40% Y4); exercisable within 3 years of vesting
Aye Finance Employee Stock Options
Aye Finance's employee welfare trust transferred 89,501 equity shares to grantees on exercising ESOP options. The share capital remains unchanged, so no new issuance occurs.
Aarti Pharmalabs Employee Stock Options
Aarti Pharmalabs granted 850 stock options to employees under its PSOP 2023 at Rs.5 exercise price. This is an employee incentive grant, not a capital raise.
OnEMI Technology Solutions Employee Stock Options
OnEMI Technology allotted 69,000 equity shares on exercise of employee stock options under the Kissht ESOP 2022 plan. The shares rank pari passu with existing equity.
Bliss GVS Pharma Employee Stock Options
Bliss GVS Pharma seeks shareholder approval via postal ballot for new employee stock option plans 2026. Up to 26,50,000 options are proposed; voting closes November 27, 2026.
Bandhan Bank Employee Stock Options
Bandhan Bank's board granted 32,98,871 stock options under ESOP Series 1 (Tranche 9) at Rs 151.91 per option. The options vest over four years, with each option convertible into one equity share.